5.0
AbbVie Inc., headquartered in the United States, is a global biopharmaceutical company operating in the healthcare sector, focused on the research, development, manufacturing, and commercialization of innovative medicines.
With a global workforce of approximately 47,000 employees, the company operates in over 70 countries, providing solutions for the treatment of complex medical conditions.
AbbVie’s portfolio features cutting-edge therapies across multiple medical specialties, with Humira standing out as its flagship product. This biologic medication is used in the treatment of autoimmune diseases and is complemented by other therapies targeting rheumatoid arthritis, psoriasis, gastrointestinal disorders, oncology, neurological diseases, and antiviral treatments.
The company makes significant investments in research and development (R&D) to drive the creation of next-generation medicines and advanced health solutions.
With a strong global presence, AbbVie maintains a robust production and R&D infrastructure across North America, Europe, Asia, and Latin America.
AbbVie is publicly traded on the New York Stock Exchange (NYSE) under the ticker ABBV.
History and Founding of AbbVie Inc.
AbbVie Inc. was founded in 2013 as a strategic spin-off from Abbott Laboratories, a company with more than a century of experience in the pharmaceutical sector.
The separation was designed to allow AbbVie to focus exclusively on innovative specialty pharmaceuticals, while Abbott continued operating in healthcare and nutrition products.
In its early years, AbbVie faced the challenge of establishing itself as an independent entity, but quickly rose to global prominence, driven by the continued success of Humira, which became one of the best-selling pharmaceutical products in the world.
Since its founding, AbbVie has expanded globally, investing heavily in innovation and strategic acquisitions to diversify its product pipeline.
One of the company’s most notable acquisitions occurred in 2020, with the purchase of Allergan, significantly enhancing AbbVie’s position in the aesthetics and neurology sectors. The acquisition brought iconic brands like Botox into AbbVie’s portfolio.
In recent years, the company has focused on diversifying its revenue streams, with investments in biotechnology, targeted therapies, and expanding its footprint in oncology and neuroscience.
Between 2020 and 2024, AbbVie increased efforts to address patent expiration challenges by advancing new therapeutic areas and forming strategic partnerships to maintain its competitive edge in the global biopharma market.
Today, AbbVie continues to invest in R&D, aiming to deliver innovative treatments for complex conditions, while reinforcing its position as one of the most prominent companies in the global biopharmaceutical industry.
Additional Information
The Company AbbVie Inc. (United States), is listed on NYSE with a market cap of $ 385.49 Billions, having an equity of $ -138.00 Millions.
With a total of 47.000 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 58.33 Billions, which generated a profit in the amount of $ 3.76 Billions.
As for its main indicators, the Company has a P/E ratio of 102.44, a P/BV ratio of -2,793.44 and in the last 12 months the dividend yield of ABBV was at 2.97%.
The Company is traded internationally through the ticker ABBV.
